Get the Stockscreener App
1.13
3.42%
-0.04
Allogene Therapeutics Inc stock is traded at $1.13, with a volume of 1.59M.
It is down -3.42% in the last 24 hours and up +9.71% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.17
Open:
$1.16
24h Volume:
1.59M
Relative Volume:
0.42
Market Cap:
$250.73M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.533
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-1.74%
1M Performance:
+9.71%
6M Performance:
-45.15%
1Y Performance:
-57.52%
1-Day Range:
$1.12
$1.16
1-Week Range:
$1.09
$1.17
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.13 | 246.29M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? - Yahoo Finance
Q3 EPS Estimate for Allogene Therapeutics Lifted by Analyst - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Trendlines Converge — Decision Point for Allogene Therapeutics Inc.2025 Market WrapUp & Consistent Profit Trading Strategies - beatles.ru
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines - Nasdaq
Allogene Therapeutics Inc. Hits Price Floor — Bounce IncomingJuly 2025 Big Picture & Proven Capital Preservation Methods - beatles.ru
Momentum Screeners Rank Allogene Therapeutics Inc. in Top 5 TodayJuly 2025 Analyst Calls & Risk Managed Trade Strategies - beatles.ru
Frazier Life Sciences Management L.P. Buys 1,001,000 Shares of Allogene Therapeutics, Inc. $ALLO - MarketBeat
Custom Dashboard Highlights Allogene Therapeutics Inc. Price MomentumAnalyst Upgrade & Precise Trade Entry Recommendations - beatles.ru
Visual analytics tools that track Allogene Therapeutics Inc. performance2025 Earnings Impact & Fast Gaining Stock Reports - Newser
Why is Allogene Therapeutics Inc. stock going upEarnings Risk Report & Reliable Volume Spike Trade Alerts - خودرو بانک
Momentum divergence signals in Allogene Therapeutics Inc. chart2025 Dividend Review & Free Daily Entry Point Trade Alerts - Newser
Key metrics from Allogene Therapeutics Inc.’s quarterly dataPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
How institutional ownership impacts Allogene Therapeutics Inc. stockJuly 2025 Fed Impact & Verified Momentum Watchlists - Newser
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia - The Globe and Mail
Is Allogene Therapeutics Inc. reversing from oversold territoryGap Up & Daily Oversold Bounce Ideas - Newser
Is it too late to sell Allogene Therapeutics Inc.2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
Can Allogene Therapeutics Inc. outperform under higher oil pricesBull Run & Daily Chart Pattern Signal Reports - خودرو بانک
Visualizing Allogene Therapeutics Inc. stock with heatmapsRate Cut & Daily Profit Maximizing Trade Tips - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they mean2025 Earnings Surprises & Verified Entry Point Signals - Newser
Using economic indicators to assess Allogene Therapeutics Inc. potentialMarket Volume Summary & Entry and Exit Point Strategies - Newser
Exit strategy if you’re trapped in Allogene Therapeutics Inc.July 2025 Levels & Precise Buy Zone Identification - Newser
Is Allogene Therapeutics Inc. stock influenced by commodity pricesLong Setup & Weekly Momentum Stock Picks - خودرو بانک
Order flow analysis tools used on Allogene Therapeutics Inc.Product Launch & Real-Time Stock Movement Alerts - Newser
Will Allogene Therapeutics Inc. outperform its industry peersJuly 2025 Big Picture & Daily Volume Surge Signals - خودرو بانک
Intraday pattern recognizer results for Allogene Therapeutics Inc.2025 Technical Patterns & Real-Time Volume Analysis Alerts - Newser
Allogene Therapeutics Inc. stock trendline breakdown2025 Support & Resistance & Momentum Based Trading Signals - Newser
| MarketBeat - MarketBeat
Will Allogene Therapeutics Inc. benefit from current market trendsDividend Hike & Weekly Momentum Stock Picks - خودرو بانک
Will Allogene Therapeutics Inc. outperform the marketJuly 2025 Outlook & Safe Capital Preservation Plans - Newser
Can Allogene Therapeutics Inc. be the next market leaderWeekly Profit Recap & Capital Efficient Trading Techniques - خودرو بانک
Why Allogene Therapeutics Inc. is moving todayJobs Report & High Accuracy Trade Alerts - Newser
Real time pattern detection on Allogene Therapeutics Inc. stockMarket Growth Report & Reliable Price Breakout Alerts - Newser
What MACD signals say about Allogene Therapeutics Inc.2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - Newser
Should you hold or exit Allogene Therapeutics Inc. nowTrade Ideas & Low Risk Investment Opportunities - Newser
Should you wait for a breakout in Allogene Therapeutics Inc.2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
What earnings revisions data tells us about Allogene Therapeutics Inc.Weekly Trade Summary & Detailed Earnings Play Strategies - Newser
Has Allogene Therapeutics Inc. found a price floorJuly 2025 Highlights & Free Real-Time Market Sentiment Alerts - Newser
What momentum shifts mean for Allogene Therapeutics Inc.Weekly Trade Analysis & Low Drawdown Momentum Ideas - Newser
Allogene Therapeutics Inc. stock trend outlook and recovery pathWeekly Risk Report & AI Based Buy and Sell Signals - Newser
Allogene Therapeutics Inc. stock outlook for YEAREarnings Performance Report & Fast Entry Momentum Trade Alerts - Newser
Evaluating Allogene Therapeutics Inc. with trendline analysisPortfolio Profit Report & Smart Allocation Stock Tips - Newser
Is Allogene Therapeutics Inc. building a consolidation baseWeekly Trading Summary & Daily Profit Focused Stock Screening - Newser
How is Allogene Therapeutics Inc. managing supply chain issuesJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - خودرو بانک
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):